WO2025215582 - SUBSTITUTED PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE
National phase entry is expected:
Publication Number
WO/2025/215582
Publication Date
16.10.2025
International Application No.
PCT/IB2025/053791
International Filing Date
10.04.2025
Title **
[English]
SUBSTITUTED PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE
[French]
COMPOSÉS PYRAZOLOPYRIDINE ET PYRAZOLOPYRIMIDINE SUBSTITUÉS ET LEUR UTILISATION
Applicants **
GT GAIN THERAPEUTICS SA
Inventors
GARCÍA COLLAZO, Ana Maria
CARRILLO ARREGUI, Jokin
TRAPERO PUIG, Ana
CUBERO JORDÀ, Elena
ÁLVAREZ GARCÍA, Daniel
MORENO MOLLÓ, Immaculada Montserrat
Priority Data
24382380.4
11.04.2024
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5767 | |
| EPO | Filing, Examination, Granting | 81850 | |
| Japan | Filing, Examination, Granting | 4487 | |
| South Korea | Filing, Examination, Granting | 6580 | |
| USA | Filing, Examination, Granting | 41490 |
Total:
140,174
Contact Us
Abstract[English]
, m, and n are defined as set forth in the specification, and their use in the treatment and/or prevention of diseases and conditions associated with the alteration of the activity of β-glucocerebrosidase.[French]
, m et n sont tels que définis dans la description, et leur utilisation dans le traitement et/ou la prévention de maladies et d'états associés à l'altération de l'activité de la β-glucocérébrosidase.